🏭 This facility boosts Lonza’s mammalian manufacturing capacity in the U.S., enhancing their West Coast presence.
🌍 The site adds to Lonza’s existing operations in New Hampshire and its global network in Europe and Asia.
💰 Lonza plans to invest $591 million to upgrade and expand the facility’s capabilities.
Introduction:
Lonza, a prominent player in the contract development and manufacturing of pharmaceuticals, has successfully completed the acquisition of Roche’s Vacaville, California, biologics manufacturing facility for $1.2 billion. This strategic move significantly enhances Lonza’s manufacturing capacity and extends its presence in the U.S. biotechnology sector.
- The acquisition of the Vacaville site expands Lonza’s capabilities in mammalian manufacturing, creating a substantial commercial presence on the West Coast.
- The facility features a bioreactor capacity of approximately 330,000 liters, positioning it among the largest biologics manufacturing sites globally.
- The site will support the manufacturing of late-stage clinical and commercial products, further bolstering Lonza’s existing international network.
- Lonza plans to invest around CHF 500 million to enhance the Vacaville facility’s capabilities for the next generation of mammalian biologics therapies.
- The existing products manufactured at the site will continue to be supplied to Roche with phased volume commitments as Lonza transitions to serving new customers.
Conclusion:
The acquisition of the Vacaville facility signifies a pivotal advancement for Lonza in reinforcing its manufacturing capabilities in the burgeoning biologics market. With significant investments planned for facility upgrades, Lonza is well-positioned to meet the growing demand for complex biologics, ultimately benefiting its customers and shareholders alike.
